Kalincik, T., Brown, J. W. L., Robertson, N., Willis, M., Scolding, N., Rice, C. M., . . . Coles, A. (2017). Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: A cohort study. Lancet neurology, 16(4), 271-281. https://doi.org/10.1016/S1474-4422(17)30007-8
Citace podle Chicago (17th ed.)Kalincik, Tomas, et al. "Treatment Effectiveness of Alemtuzumab Compared with Natalizumab, Fingolimod, and Interferon Beta in Relapsing-remitting Multiple Sclerosis: A Cohort Study." Lancet Neurology 16, no. 4 (2017): 271-281. https://doi.org/10.1016/S1474-4422(17)30007-8.
Citace podle MLA (9th ed.)Kalincik, Tomas, et al. "Treatment Effectiveness of Alemtuzumab Compared with Natalizumab, Fingolimod, and Interferon Beta in Relapsing-remitting Multiple Sclerosis: A Cohort Study." Lancet Neurology, vol. 16, no. 4, 2017, pp. 271-281, https://doi.org/10.1016/S1474-4422(17)30007-8.